Lexapro And Strokes: What's The Connection?

Antidepressants like Lexapro have been found to increase the risk of certain types of strokes, particularly in young adults with PTSD. Lexapro, also known as Escitalopram, is a selective serotonin reuptake inhibitor (SSRI) and research suggests that SSRIs may increase the risk of hemorrhagic strokes, which occur when a weakened blood vessel ruptures and bleeds into the brain. However, it's important to note that the absolute risk of these strokes is very low, and the benefits of SSRIs may outweigh the risks for many individuals.

Lexapro may help preserve brain function after a stroke

Lexapro, also known as escitalopram, is an antidepressant that may help preserve brain function after a stroke. In a study conducted by researchers at the University of Iowa, 129 stroke patients were given either Lexapro, a placebo, or counselling-type therapy. The study found that those who took Lexapro within three months of their stroke scored higher on tests of thinking, learning, and memory function, as well as verbal and visual memory tests. This improvement was independent of any improvement in depression symptoms.

Lexapro is a selective serotonin reuptake inhibitor (SSRI) and is thought to cause changes in key brain structures needed for memory and thinking, including the visual cortex, hippocampus, and cerebral cortex. This may help explain the memory improvements seen in the study. The researchers noted that further study is needed to confirm these findings.

The use of antidepressants as a restorative therapy after a stroke is of growing interest. Restorative therapies are administered during the first few months after a stroke, which is the period when the greatest degree of spontaneous recovery of initial motor and cognitive deficits is observed. By reducing the number of stroke patients with significant disabilities, these therapies have the potential to significantly reduce the burden of this disease.

Lexapro may help protect key thinking functions if taken soon after a stroke

Lexapro, also known as escitalopram, is an antidepressant that may help protect key thinking functions if taken soon after a stroke. In a study conducted by researchers at the University of Iowa, 129 stroke patients were given either Lexapro, a placebo, or counselling-type therapy. The study found that those who took Lexapro within three months of their stroke scored higher on tests of thinking, learning, and memory function, as well as verbal and visual memory tests, compared to those who took a placebo or underwent therapy. This improvement was independent of any improvement in depression symptoms.

Lexapro is a selective serotonin reuptake inhibitor (SSRI) and is thought to cause changes in key brain structures needed for memory and thinking, including the visual cortex, hippocampus, and cerebral cortex. This may help explain the memory improvements seen in those who took the drug after a stroke. The researchers noted that further study is needed to confirm these findings.

Antidepressants may increase the risk of stroke recurrence

The study categorized antidepressants into four types: tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), and other antidepressants. The use of TCAs, SSRIs, and other antidepressants was found to increase the risk of stroke recurrence. Additionally, the use of multiple types of antidepressants simultaneously further elevated the risk.

It is important to note that the study had certain limitations. The history of stroke prior to 1996 was unknown, and there were potential inaccuracies in the recording of stroke diagnoses and prescriptions in the database. Furthermore, the data on antidepressant use during inpatient admissions was excluded due to the unavailability of information on the duration of use for each prescription.

While this study provides valuable insights, further research is warranted to confirm the underlying mechanisms and to assess the impact of antidepressants on recurrent stroke as a primary endpoint.

SSRIs may increase the risk of certain types of stroke

Antidepressants may increase the risk of certain types of stroke. A study published in the American Heart Association journal Stroke found that certain types of antidepressants may be better than others for treating PTSD because they carry a lower risk of stroke. The research, which looked at data from 1.1 million U.S. veterans, found that taking SSRI medication carried a 45% greater risk of hemorrhagic stroke. Another study published in Neurology found that those taking SSRIs were 51% more likely to have an intracranial hemorrhagic stroke and about 42% more likely to have an intracerebral hemorrhagic stroke than those not taking SSRIs. However, it's important to note that these types of strokes are very rare, and the actual increased risk for the average person is very low.

Antidepressants may be beneficial for stroke recovery

Selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) are commonly prescribed to aid in stroke recovery and reduce the risk of abnormal bleeding. These types of antidepressants have been found to be generally safe for most stroke survivors, according to research presented at the American Stroke Association's International Stroke Conference. The study found that people who had suffered clot-caused strokes, or ischemic strokes, and took SSRIs and/or SNRIs for post-stroke depression and anxiety did not have an increased risk of abnormal bleeding, even if they were also taking anti-clotting medication. This is reassuring for clinicians and patients, as it indicates that it is safe to prescribe these types of antidepressants early on in the recovery process.

However, the study did find an increased risk of bleeding strokes among people who were taking two blood-thinning medications, known as dual antiplatelet therapy (DAPT). Therefore, caution is needed when considering the risk-benefit profile for stroke patients receiving DAPT. Additionally, the study did not account for dosage, duration, and the number of antidepressants taken by the participants, which could be important factors in determining the safety and efficacy of these medications.

Other studies have also found potential benefits of antidepressants in stroke recovery. For example, a review of the existing evidence and mechanisms behind antidepressant use for motor recovery in stroke patients suggests that antidepressants have a positive impact on post-stroke functional recovery, regardless of the presence of depression. The review highlights the multifactorial mechanisms by which antidepressants improve motor recovery, including augmentation of cerebral blood flow, cortical excitation, and potentiation of neural growth factors, all resulting in enhanced neurogeneration.

Furthermore, clinical trials have demonstrated that antidepressants improve physical recovery and motor function independent of the presence of depression. For example, the FLAME trial found that patients who received fluoxetine for 3 months had significantly higher improvements in motor scale scores compared to those who received a placebo, with the impact of fluoxetine being independent of the status of depression in the patients. Similarly, a double-blinded randomized trial found that patients recovering from stroke who received fluoxetine, nortriptyline, or placebo for 3 months had less disability at 1 year following stroke or 9 months following the discontinuation of their antidepressant treatment, even after controlling for the presence of depression and other factors.

In summary, while further research is needed to fully understand the risks and benefits of antidepressants in stroke recovery, current evidence suggests that they may be beneficial for improving functional recovery and reducing disability. However, it is important to carefully consider the potential risks and side effects and consult with a healthcare professional before taking any medications.

Frequently asked questions